Cidara Therapeutics, Inc. announced on September 3, 2025, that it will deliver two oral presentations, including a late-breaking abstract, at the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP), held from September 17-20, 2025, in Singapore.
One presentation will detail the efficacy and safety results from the Phase 2b NAVIGATE trial of CD388 for the prevention of influenza illness in healthy adults. This will provide further insights into the positive topline results previously announced.
The second presentation will feature preclinical data demonstrating that a single prophylactic dose of CD388 provides protection against highly pathogenic bovine-origin Influenza A (H5N1) virus in the ferret model. This highlights CD388's potential as a universal preventative against pandemic influenza strains.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.